On May 12, 2026, Nature Medicine published the ATTAIN-MAINTAIN trial results. Patients who switched from weekly injectable GLP-1s (semaglutide or tirzepatide) to daily oral orforglipron maintained approximately 75–80% of their weight loss. Health improvements in blood pressure, blood sugar, and cholesterol were also largely preserved.
That's genuinely encouraging data. But let's be precise about what it means.
The 20–25% Regain Is Not Trivial
If you lost 50 pounds on an injectable GLP-1 and switched to the pill, you'd expect to regain 10–12.5 pounds. For a 40-pound loss, that's 8–10 pounds back. This isn't catastrophic, but it's not nothing — especially for patients who are psychologically attached to their lowest weight.
More importantly, the tirzepatide-to-orforglipron group regained more than the semaglutide-to-orforglipron group. This makes biological sense: tirzepatide targets two receptors (GLP-1 + GIP), while orforglipron targets one (GLP-1 only). You're downgrading from a dual-agonist to a single-agonist. Some efficacy loss is expected.
The Conflict of Interest Disclosure
The study was sponsored by Eli Lilly, which manufactures both orforglipron and tirzepatide. Lead author Dr. Louis Aronne is a paid consultant and advisory board member for Lilly. This doesn't invalidate the data — it's a rigorous phase 3b trial published in a top journal. But it means the framing naturally emphasizes the positive: "patients maintained most of their weight loss" rather than "patients regained 10+ pounds."
What This Study Doesn't Tell You
What happens if you stop the oral pill too. Based on every other GLP-1 discontinuation study, weight regain would be expected. The study shows a maintenance strategy — not an exit strategy.
When the Switch Makes Sense
- You've stabilized at your target weight on an injectable and want to transition to a less burdensome maintenance format
- You have injection fatigue, travel frequently, or find refrigeration requirements difficult
- You were on semaglutide injections (the single-target match with orforglipron is closer)
When It Doesn't
- You're still actively losing weight — injectable GLP-1s are more effective during the active loss phase
- You're on tirzepatide and every pound matters — the regain from dual-to-single agonist transition may not be acceptable
- You're looking for a way to stop medication entirely — the data doesn't support that
Wellorithm
Start with injectable GLP-1 for maximum results, with ongoing clinical support to guide any future transitions. Wellorithm helps you plan the full treatment arc.
Compare Now →